Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

0.6366 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Ther ADR

< Previous 1 2 3 4 5 6 Next >
Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET
Adaptimmune Therapeutics (NASDAQ:ADAP) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q4, Adaptimmune Therapeutics (NASDAQ:ADAP) posted sales of $1.42 million. Earnings were up 8.36%, but Adaptimmune Therapeutics still... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Adaptimmune Therapeutics: Q4 Earnings Insights
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here's what investors need to know about the announcement... 
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Mustang Bio (NASDAQ:MBIO) shares ... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Crashing Today
Investor sentiment has turned against this promising cell therapy company. 
Via The Motley Fool
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Transcript
ADAP earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Adaptimmune Therapeutics: Q3 Earnings Insights
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Why Adaptimmune Therapeutics Was Sinking This Week
Profit-taking seemed to be the general dynamic behind the biotech's 14% slide. 
Via The Motley Fool
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
Adaptimmune Therapeutics (NASDAQ:ADAP) brought in sales totaling $3.10 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 4.22%, resulting in... 
Via Benzinga
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.65% to 35,138.64 while the NASDAQ rose 0.13% to 15,383.18. The S&P also fell, dropping 0.27% to 4,522.99. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Surrozen (NASDAQ:SRZN) stock rose 33.14% to $9.64 during Tuesday's regular session. The company's market cap stands at $351.2 million. ZIOPHARM Oncology (... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.... 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares jumped 32.6% to $4.2443. The company recently... 
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:... 
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Spiking Today
The hunt for the next biotech buyout play is apparently underway. 
Via The Motley Fool
Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call Transcript
ADAP earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.